SCYNEXIS (NASDAQ:SCYX) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS

SCYNEXIS (NASDAQ:SCYX) issued its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13, Zacks reports. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Price Performance

Shares of SCYX stock traded up $0.01 during trading on Wednesday, hitting $0.91. 142,474 shares of the stock traded hands, compared to its average volume of 199,153. SCYNEXIS has a 52-week low of $0.88 and a 52-week high of $3.07. The firm has a market capitalization of $34.61 million, a P/E ratio of -1.23 and a beta of 1.67. The firm’s fifty day moving average price is $1.11 and its 200-day moving average price is $1.26.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.